Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 72Colorectal Neoplasms 43Rectal Neoplasms 41Stomach Neoplasms 38Triple Negative Breast Neoplasms 30Neoplasm Metastasis 19Esophageal Neoplasms 16Colonic Neoplasms 16Pancreatic Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Neoplasms 11Nasopharyngeal Carcinoma 11Adenocarcinoma 11Biliary Tract Neoplasms 10Adenocarcinoma Of Esophagus 9Cholangiocarcinoma 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Brain Neoplasms 6Anus Neoplasms 6Recurrence 5Gastrointestinal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4HER2-positive Breast Cancer 4Colorectal Cancer Metastatic 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Pathologic Complete Response 3Ovarian Neoplasms 3

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inoperable Locally Advanced HER2-Negative Breast Cancer × Capecitabine × 1 year × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡